Lutetium-177 Treatment for Advanced Prostate Cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a radioactive medication (177Lu-P17-088) designed to target and treat prostate cancer that has spread to other parts of the body and stopped responding to hormone therapy. The medication is guided to cancer cells using a special imaging scan, potentially offering a new treatment option for men who have already tried other standard therapies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have metastatic castration-resistant prostate cancer (cancer that has spread and worsens despite hormone-lowering treatment)
- You have already tried or cannot take at least one prior hormone therapy (like abiraterone or enzalutamide) and 1–2 chemotherapy regimens
- A special PET scan (68Ga-PSMA-11) shows your cancer cells light up with the radioactive tracer
- Your blood counts and liver/kidney function are adequate to handle this treatment
- You have a life expectancy of at least 6 months and are in fair health (ECOG status 0–2)
- You have not had recent radiation therapy or other cancer treatments within the past 4–6 weeks
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new radioactive treatment, called 177Lu-NYM032, for men with advanced prostate cancer that has spread and is no longer responding to hormone therapy. It aims to see if this treatment can slow the cancer's growth and improve outcomes.
This trial tests a radioactive drug called Lu 177 JH020002 for men with advanced prostate cancer that has spread and stopped responding to hormone therapy. The drug targets a protein on cancer cells to deliver radiation directly, possibly slowing the disease.
This trial looks at people with advanced prostate cancer that has stopped responding to hormone therapy and chemotherapy. It tests a radioactive medicine (lutetium-177 PSMA) that targets prostate cancer cells, to see what factors predict a good response.
This study looks at patients treated with a radioactive drug called 177Lu-PSMA-617 for a type of prostate cancer that has spread, stopped responding to hormone therapy, and has been treated with chemotherapy. It checks how the treatment affects the body and the tumor using images.
This early-stage trial tests a new radioactive drug (177Lu-FC516) designed to target and treat prostate cancer that has spread and is no longer responding to standard treatments. The goal is to evaluate whether it is safe and effective.
This trial tests a radioactive drug called 177Lu-PSMA-617 to see if it can help men with metastatic castration-resistant prostate cancer that has spread to the bones in a specific pattern (superscan). It's for patients who have already tried hormone therapy and have PSMA-positive tumors.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.